NCT03513016View on ClinicalTrials.gov

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

March 29, 2019

Study Completion Date

April 12, 2019

Conditions
Osteoarthritis, Knee
Interventions
DRUG

UBX0101

Investigational drug intra-articular injection

OTHER

Placebo

Diluent intra-articular injection

Trial Locations (7)

16635

Altoona Center for Clinical Research, Duncansville

33132

Well Pharma Medical Research, Miami

64114

Center for Pharmaceutical Research, Kansas City

75231

Metroplex Clinical Research Center, Dallas

89119

Clinical Research Consortium, Las Vegas

91942

BioSolutions Clinical Research Center, La Mesa

92020

TriWest Research Associates, El Cajon

All Listed Sponsors
lead

Unity Biotechnology, Inc.

INDUSTRY

NCT03513016 - A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter